Compare CubeSmart (CUBE) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CubeSmart vs Incyte Corporation — how do they compare? CubeSmart trades at $37.56 (market cap $8.38B), while Incyte Corporation trades at $112.75 (market cap $22.99B). The key difference: Incyte Corporation is far larger — about 2.7× CubeSmart's market cap, and CubeSmart pays a 5.69% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold CubeSmart for 89 Days and Incyte Corporation for 33 Days on average.
| CUBE | INCY | |
|---|---|---|
Market Cap | $8.38B | $22.99B |
Volume | 2,231,307 | 1,274,487 |
Sector | Real Estate | Health |
52-Week High | $42.50 | $129.93 |
52-Week Low | $35.36 | $83.80 |
Typical Hold Time | 89 Days | 33 Days |
Enterprise Value | $11.91B | $18.50B |
Dividend Yield | 5.69% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CubeSmart (CUBE) trades at $37.51, down 0.66% on the day, with a bearish technical signal but improving operational trends. The REIT reported Q2 2026 earnings beats and raised full-year guidance, though funds from operations slightly missed estimates. Valuation ratios like P/E of 25.33 and P/S of 7.48 are elevated, while profitability remains solid with a 29.41% net income margin. Recent news highlights institutional buying and debates on REIT valuations amid AI sector shifts.
Outlook is mixed: analyst consensus targets $44.00 with a 'Buy' lean, but technicals and macroeconomic headwinds pose risks. The stock offers a 5.4% dividend yield, yet same-store NOI declines and high debt levels warrant caution. Upside depends on sustained occupancy gains and moderating supply pressures in the self-storage sector.
INCY trades at $112.75, up 0.02% on the day, with a bullish technical signal from oscillators but bearish moving averages. The company reported strong Q2 2026 earnings, beating expectations with EPS of $3.09 versus $2.15, and revenue growth from $5.14B in 2025 to a projected $5.8B in 2026. Recent FDA approval for Atebrioz and a strategic push for post-JAKAFI growth highlight pipeline progress. Valuation ratios appear reasonable with a P/E of 14.45 and EV/EBITDA of 8.94.
Outlook is positive with a consensus price target of $132.07, implying 17% upside, supported by 52% analyst buy ratings. Risks include reliance on JAKAFI, which loses exclusivity after 2029, and near-term earnings volatility as seen in the Q4 2025 miss. Strong cash flow and profitability metrics suggest resilience, but execution on pipeline diversification is critical for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About CubeSmart
CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Most of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. CubeSmart derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.
Read more on CUBE →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
